patients living in the community and found that they exercised less, smoked more, and had less healthy diets, compared with normal control subjects (5). Lindenmayer and others proposed an additive risk model to identify risk factors that increase the probability of schizophrenia patients' developing DM (6) . Ethnicity, family history of diabetes, history of glucose dysregulation, and preexisting hypertension were all suggested to increase the risk of type 2 DM.
Another putative factor may be psychotropic medications: it has been reported that chlorpromazine and lithium impair glucose tolerance (7) . The mechanism of action of these drugs is much debated and includes increased peripheral resistance to insulin, which may be secondary to the weight gain in these patients. However, weight gain is not a prerequisite for the development of hyperglycemia and diabetes (8) . The newer atypical drugs may contribute directly to hyperglycemia by inhibiting glucose uptake in different cell types. Recent evidence suggests that the antipsychotics may do so by binding to and blocking the glucose transporter protein (9) .
This study aimed to establish the prevalence of DM and impaired glucose tolerance in a population of schizophrenia patients and to elucidate some of the factors associated with hyperglycemia.
Method
We surveyed 607 patients; residents of the long-stay wards in Woodbridge Hospital, Singapore. Two psychiatrists independently verified that all the patients fulfilled DSM-IV criteria for schizophrenia. The prevalence of DM (that is, those patients with a chart diagnosis of DM) was found to be 4.9% (n = 30). For this study, we recruited patients who were able to give an informed, written consent and who had no documented chart diagnosis of diabetes, impaired glucose tolerance, significant physical illness, or history of drug or alcohol abuse. We subsequently included 194 patients in the study. None had received any atypical neuroleptics, either in the past or at the time of the study.
We reviewed the case records to obtain information on age, sex, illness-onset age, illness duration, and current medication status. We calculated body mass index (BMI) after using the same scale to record the weight and height of all patients. Patients were given an oral glucose tolerance test after an overnight fast. Fasting blood glucose and insulin levels were determined at the start of the testing period. We used the World Health Organization (WHO) diagnostic classification criterion for the Oral Glucose Tolerance Test (OGTT) to classify DM and impaired glucose tolerance (10).
Results
Of the 194 patients, 155 were men and 39 were women. Their mean (SD) age was 55.5 (8.7) years, with an age range of 33 to 83 years. The mean age at onset of schizophrenia was 22.6 years, and the mean duration of illness was 31.8 years.
The overall prevalence of diabetes was 16% (n = 31), and the overall prevalence of impaired glucose tolerance was 30.9% (n = 60). Of the 31 diabetes patients, 22 were men, and 9 were women. There was no significant effect of sex or ethnicity on diabetes (P 2 = 1.9, P = 0.17 and P 2 = 0, P = 1.0, respectively). 
Discussion
According to the National Health Survey, the DM morbidity rate in the general population of Singapore was 9%, and the rate of impaired glucose tolerance was 15% (12) . However, the prevalence rates of DM and impaired glucose tolerance in our study were much higher-16% and 30.9%, respectively. The mean age of patients in our study was 55.5 years; in the comparative population (that is, those aged 50 to 59 years), the prevalence of diabetes was 21.8%.
We found age to be associated with diabetes, but we found no association with sex, ethnicity, or daily neuroleptic dosage. Tan and others have reported the increased risk of DM with increased age in the Singapore general population (13) . These authors report the highest prevalence of DM to be in Asian Indians, although a significant ethnic difference between Chinese subjects and the other 2 ethnic groups (that is, Malays and Indians) could be demonstrated only in women.
Obesity is another well-established risk factor that can lead to insulin insensitivity, glucose intolerance, and subsequently, DM. However, the weight and BMI of patients with disordered glucose homeostasis and of those without did not differ significantly. Almost all the patients had been institutionalized for long periods and within the same environment, and their similar diets and lifestyles could account for this lack of variance in weight and BMI. However, Mukherjee and others, reporting similar findings, suggest that individual biological differences in response to diet, rather than diet per se, may be more critical in determining the risk of DM in these patients (3).
Our study highlights a high rate of DM among patients with schizophrenia. This comorbidity is associated with an increased risk of hypertension and coronary heart disease, which in turn may contribute to the higher mortality of patients with schizophrenia. Clinicians should be vigilant for the early symptoms of DM in this population, and regular glucose monitoring should be considered for those who have risk factors for developing DM.
Résumé : Diabète sucré et intolérance au glucose chez les patients souffrant de schizophrénie
Objectifs : Cette étude visait à établir la prévalence du diabète sucré (DS) et de l'intolérance au glucose chez les patients souffrant de schizophrénie ainsi qu'à élucider certains des facteurs associés à l'hyperglycémie.
Méthodes : Nous avons étudié un échantillon de 194 patients souffrant de schizophrénie. Nous avions déterminé à jeun la glycémie et les niveaux d'insuline au début de la période de l'étude; et nous avons administré aux patients un test oral de tolérance au glucose, à jeun le matin.
Résultats : La prévalence globale du diabète et de l'intolérance au glucose chez ces patients était de 16,0 % et de 30,9 %, respectivement. Ces taux étaient plus élevés que ceux déclarés dans la population générale. Les patients ayant une homéostasie du glucose désordonnée étaient significativement plus âgés (P = 0,005, test de Kruskal-Wallis). Il n'y avait pas d'effet significatif selon le sexe ou l'origine ethnique sur le diabète.
Conclusions : Nos résultats indiquent que les patients souffrant de schizophrénie sont plus susceptibles de développer le DS. Nous prévenons les cliniciens de tenir compte du risque accru et d'être vigilants quant à ce développement.
